| Identification | Back Directory | [Name]
NKP-1339 | [CAS]
197723-00-5 | [Synonyms]
IT-139
KP 1339
CS-2765
NKP-1339
KP1339;KP 1339;NKP1339;NKP 1339;KP-1339 | [Molecular Formula]
C14H12Cl4N4NaRu | [MDL Number]
MFCD25976832 | [MOL File]
197723-00-5.mol | [Molecular Weight]
502.144 |
| Hazard Information | Back Directory | [Uses]
BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu[1]. | [in vivo]
BOLD-100 (intravenous injection; 30 mg/kg; once a week; 42sdays) combines with the multi-kinase inhibitor sorafenib and exhibits a further anticancer activity when compares to the BOLD-100 treatment alone in Hep3B xenografts grown in Balb/c SCID mice [2]. | Animal Model: | Hep3B xenograft in Balb/c mice[2] | | Dosage: | 30 mg/kg | | Administration: | Intravenous injection | | Result: | Had synergistic activity of KP1339 with sorafenib?in vivo. |
| [References]
[1] Robert Trondl, et al. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chemical Science. Chemical Science
[2] Heffeter P, et al. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. Eur J Cancer. 2013 Oct;49(15):3366-75. DOI:10.1016/j.ejca.2013.05.018 |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|